Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc.verified

RCKT

Price:

$25.58

Market Cap:

$2.32B

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated ...[Read more]

Industry

Biotechnology

IPO Date

2015-02-18

Stock Exchange

NASDAQ

Ticker

RCKT

The PE Ratio as of July 2024 (TTM) for Rocket Pharmaceuticals, Inc. (RCKT) is -8.98

According to Rocket Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -8.98. This represents a change of 3.47% compared to the average of -8.68 of the last 4 quarters.

Rocket Pharmaceuticals, Inc. (RCKT) Historical PE Ratio (quarterly & annually)

How has RCKT PE Ratio performed in the past?

The mean historical PE Ratio of Rocket Pharmaceuticals, Inc. over the last ten years is -8.43. The current -8.98 PE Ratio has changed 10.56% with respect to the historical average. Over the past ten years (40 quarters), RCKT's PE Ratio was at its highest in in the September 2015 quarter at -0.95. The PE Ratio was at its lowest in in the June 2021 quarter at -20.22.

Quarterly (TTM)
Annual

Average

-8.43

Median

-7.99

Minimum

-20.71

Maximum

-2.39

Rocket Pharmaceuticals, Inc. (RCKT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Rocket Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 227.05%

Maximum Annual PE Ratio = -2.39

Minimum Annual Increase = -64.52%

Minimum Annual PE Ratio = -20.71

Quarterly (TTM)
Annual
YearPE RatioChange
2023-10.2568.63%
2022-6.08-25.32%
2021-8.14-60.69%
2020-20.7154.50%
2019-13.4071.14%
2018-7.83227.05%
2017-2.39-37.08%
2016-3.8124.70%
2015-3.05-64.52%
2014-8.6029.76%

Rocket Pharmaceuticals, Inc. (RCKT) Average PE Ratio

How has RCKT PE Ratio performed in the past?

The current PE Ratio of Rocket Pharmaceuticals, Inc. (RCKT) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

3-year avg

-8.16

5-year avg

-11.72

10-year avg

-8.43

Rocket Pharmaceuticals, Inc. (RCKT) PE Ratio vs. Peers

How is RCKT’s PE Ratio compared to its peers?

Rocket Pharmaceuticals, Inc.’s PE Ratio is less than uniQure N.V. (-1.33), greater than Rhythm Pharmaceuticals, Inc. (-10.96), less than Solid Biosciences Inc. (-3.86), less than MeiraGTx Holdings plc (-4.07), greater than Vaxcyte, Inc. (-21.71), greater than Larimar Therapeutics, Inc. (-11.56), less than Syndax Pharmaceuticals, Inc. (-8.33), greater than Merus N.V. (-21.70), less than Sutro Biopharma, Inc. (-2.12), less than Stoke Therapeutics, Inc. (-6.19), less than Pliant Therapeutics, Inc. (-4.57), greater than Dyne Therapeutics, Inc. (-13.85), greater than Cytokinetics, Incorporated (-10.94), greater than Revolution Medicines, Inc. (-16.08), less than REGENXBIO Inc. (-2.43), less than Day One Biopharmaceuticals, Inc. (-6.52), less than Replimune Group, Inc. (-2.93), greater than Mirum Pharmaceuticals, Inc. (-11.99), less than Viridian Therapeutics, Inc. (-4.47), less than Inozyme Pharma, Inc. (-4.65),

Build a custom stock screener for Rocket Pharmaceuticals, Inc. (RCKT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rocket Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Rocket Pharmaceuticals, Inc. (RCKT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Rocket Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Rocket Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Rocket Pharmaceuticals, Inc. (RCKT)?

What is the highest PE Ratio for Rocket Pharmaceuticals, Inc. (RCKT)?

What is the 3-year average PE Ratio for Rocket Pharmaceuticals, Inc. (RCKT)?

What is the 5-year average PE Ratio for Rocket Pharmaceuticals, Inc. (RCKT)?

How does the current PE Ratio for Rocket Pharmaceuticals, Inc. (RCKT) compare to its historical average?